Cargando…

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease

OBJECTIVE: We analyzed the longitudinal profile of Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers in early Parkinson's disease (PD) compared with healthy controls (HCs) and tested baseline CSF biomarkers for prediction of clinical decline in PD. METHODS: Amyloid‐β 1 to 42 (A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Irwin, David J., Fedler, Janel, Coffey, Christopher S., Caspell‐Garcia, Chelsea, Kang, Ju Hee, Simuni, Tanya, Foroud, Tatiana, Toga, Arthur W., Tanner, Caroline M., Kieburtz, Karl, Chahine, Lana M., Reimer, Alyssa, Hutten, Samantha, Weintraub, Daniel, Mollenhauer, Brit, Galasko, Douglas R., Siderowf, Andrew, Marek, Kenneth, Trojanowski, John Q., Shaw, Leslie M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497251/ https://www.ncbi.nlm.nih.gov/pubmed/32542885 http://dx.doi.org/10.1002/ana.25811

Ejemplares similares

Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
por: Brumm, Michael C., et al.
Publicado: (2023)

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023)

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study
por: Weintraub, Daniel, et al.
Publicado: (2023)

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
por: Marek, Kenneth, et al.
Publicado: (2018)

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
por: Mollenhauer, Brit, et al.
Publicado: (2020)

Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder
por: Chahine, Lana M., et al.
Publicado: (2020)

Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
por: Kremer, Thomas, et al.
Publicado: (2021)

Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2022)

Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
por: Bartl, Michael, et al.
Publicado: (2021)

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease
por: Simuni, Tanya, et al.
Publicado: (2016)

Proposal for a Biologic Staging System of Parkinson’s Disease
por: Chahine, Lana M., et al.
Publicado: (2023)

Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
por: Chahine, Lana M., et al.
Publicado: (2018)

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
por: Weintraub, Daniel, et al.
Publicado: (2020)

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
por: Caspell-Garcia, Chelsea, et al.
Publicado: (2017)

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
por: Chahine, Lana M., et al.
Publicado: (2018)

In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
por: Chahine, Lana M., et al.
Publicado: (2020)

A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients
por: Alcalay, Roy N., et al.
Publicado: (2020)

Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older
por: Brumm, Michael C., et al.
Publicado: (2023)

Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors
por: Atri, Roozbeh, et al.
Publicado: (2022)

Status of Current Biofluid Biomarkers in Parkinson's Disease
por: Mollenhauer, Brit
Publicado: (2023)

Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay
por: Chahine, Lana M., et al.
Publicado: (2023)

Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson’s Disease Research: The Fox Insight Cohort Experience
por: Dobkin, Roseanne D., et al.
Publicado: (2020)

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
por: Eidson, Lori N., et al.
Publicado: (2017)

Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease
por: Lim, Nicholas S., et al.
Publicado: (2016)

A proteogenomic view of Parkinson’s disease causality and heterogeneity
por: Kaiser, Sergio, et al.
Publicado: (2023)

Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person
por: Chahine, Lana M., et al.
Publicado: (2020)

Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease
por: Picillo, Marina, et al.
Publicado: (2022)

Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder
por: Chahine, L. M., et al.
Publicado: (2019)

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease
por: Irwin, David J., et al.
Publicado: (2013)

Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype
por: Goodman, Andrew D., et al.
Publicado: (2021)

Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson’s Disease
por: Gallagher, Julia, et al.
Publicado: (2021)

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial
por: Simuni, Tanya, et al.
Publicado: (2020)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o4f45hqhe1bb0kntu278g198c4